CSIMarket
 
Monopar Therapeutics Inc   (MNPR)
Other Ticker:  
 
 
Price: $0.6510 $-0.06 -7.921%
Day's High: $0.76 Week Perf: -28.59 %
Day's Low: $ 0.65 30 Day Perf: 92.95 %
Volume (M): 266 52 Wk High: $ 2.99
Volume (M$): $ 173 52 Wk Avg: $0.74
Open: $0.70 52 Wk Low: $0.27



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 14
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Monopar Therapeutics Inc
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of cancer. The company focuses on developing antibody-drug conjugates (ADCs) and immune-modulating therapies with the aim of improving patient outcomes. Monopar's lead product candidate, Validive, is an investigational drug for the treatment of severe oral mucositis caused by chemoradiotherapy. The company is also involved in several collaborations and partnerships to further develop its product pipeline. Overall, Monopar Therapeutics is committed to developing innovative therapies that can address unmet medical needs in the field of oncology.


   Company Address: 1000 Skokie Blvd., Suite 350 Wilmette 60091 IL
   Company Phone Number: 388-0349   Stock Exchange / Ticker: NASDAQ MNPR
   MNPR is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Monopar Breakthrough: Therapeutic Isotope Shows Highly Targeted Tumor Uptake in Groundbreaking Preclinical Study

Published Tue, Mar 5 2024 12:00 PM UTC

In a major step forward for cancer therapeutics, Monopar Therapeutics Inc. has announced significant progress in its MNPR-101 Radiopharma Program. The company revealed positive preclinical imaging data showcasing the exceptional uptake of a therapeutic radioisotope when bound to its proprietary uPAR targeting agent, MNPR-101. This breakthrough is expected to pave the way for...

Clinical Study

Prof. Rodney Hicks to Lead Monopar's MNPR-101-Zr Radiopharma Clinical Trial: Advancing Precision Cancer Treatments

Published Tue, Feb 27 2024 12:00 PM UTC

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in developing innovative cancer treatments, has announced the appointment of renowned radiopharmaceutical physician Professor Rodney Hicks as the lead investigator for the MNPR-101-Zr Phase 1 dosimetry clinical trial. This significant development aims to evaluate the targeting ability of MNPR-...

Clinical Study

Monopar Therapeutics Initiates First-in-Human Phase 1 Trial of MNPR-101-Zr: A Promising Radiopharmaceutical for Advanced Cancers

Published Tue, Feb 20 2024 1:00 PM UTC

Monopar Therapeutics Begins First-in-Human Phase 1 Trial of Innovative Radiopharmaceutical MNPR-101-Zr in Advanced CancersIn a groundbreaking development for cancer treatment, Monopar Therapeutics Inc. has recently obtained clearance from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 dosimetry trial for its novel radiopharmaceutical, MNPR-101-...

Monopar Therapeutics Inc

Major Pharmaceutical Preparations Company Shows Significant Improvement, Operating Deficit Narrows to $-2.407345 Million by Third Quarter of 2023

Monopar Therapeutics Inc: A Bearish Outlook for Shareholders
The recent performance of Monopar Therapeutics Inc has raised concerns among stockholders, who were caught unaware by certain adjustments that took place during the July to September 30, 2023 reporting season. The company's financial statements reveal an operating deficit of $-2.065994 million, highlighting the fact that Monopar Therapeutics Inc could have been managing its business operations more efficiently during this time frame, compared to the previous year ending September 30, 2022.
The operating deficit in the third quarter of 2023 showed a slight improvement from the preceding year, indicating that losses have indeed decreased. This finding was particularly crucial for investors as it provided a glimmer of hope amidst a string of disappointing financial results. With a deficit of $-2.407345 million recorded in the same period last year, the reduction to $-2.065994 million offers some relief. However, it is important to note that the company still has a long way to go in terms of profit generation and sustainable growth.

Monopar Therapeutics Inc

Monopar Therapeutics Inc Sees Impressive Operating Deficit Improvement of $-2.763348 Million in Second Quarter 2023

onopar Therapeutics Inc. has recently released its financial report, highlighting positive improvements in its operating deficit during the fiscal period spanning April to June 2023. According to the report, shareholders have closely monitored the company's operating deficit, which has shown significant improvement compared to the previous year.
During the earnings cycle from April to June 2023, investors had not anticipated any changes at Monopar Therapeutics Inc. However, the company managed to reduce its operating deficit from $-2.763348 million to $-2.328209 million over the same period, reflecting increased efficiency and growth prospects.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com